LEADER 01534nam  2200421   450 
001 9910698376603321
005 20221024222836.0
035   $a(CKB)3450000000002512
035   $a(NjHacI)993450000000002512
035   $a(OCoLC)168035840
035   $a(EXLCZ)993450000000002512
100   $a20221024d2009      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAspirin for the primary prevention of cardiovascular events $ean update of the evidence for the U.S. preventive services task force /$fTracy Wolff, Therese Miller, Stephen Ko
210  1$aRockville (MD) :$cAgency for Healthcare Research and Quality (US),$d[2009]
210  4$dİ2009
215   $a1 online resource (254 pages) $cillustrations
300   $aTitle from title screen (viewed on Sept. 6, 2007).
300   $a"January 2002."
320   $aIncludes bibliographical references.
517   $aAspirin for the Primary Prevention of Cardiovascular Events
606   $aCardiovascular system$xDiseases
615  0$aCardiovascular system$xDiseases.
676   $a616.1
700   $aWolff$b Tracy A.$01351961
702   $aMiller$b Therese
702   $aKo$b Stephen
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910698376603321
996   $aAspirin for the primary prevention of cardiovascular events$93143886
997   $aUNINA